Anti-ELOVL3 [V61 P2B3*D10]
Invented by Ayham Alnabulsi from Vertebrate Antibodies Limited
Invented at Vertebrate Antibodies Limited
- Datasheet
- References (2)
- Inventor Info
Info
![Immunohistochemistry of formalin-fixed, paraffin-embedded human colorectal cancer tissue using anti-ELOVL3 [V61 P2B3*D10] showing strong cytoplasmic staining.](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,q_auto/a6066eb0-1cf2-4663-81d2-fd122bb28449.jpg)
![Immunohistochemistry was performed on normal colon (A) and primary colorectal tumour (B) tissue using anti-ELOVL3 [V61 P2B3*D10]. Cytoplasmic localisation of ELOVL3 was observed.](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,q_auto/7b350a61-0a24-4bd4-b8ea-115e7b61ae27.jpg)
![Immunohistochemistry image showing strong cytoplasmic positivity in primary colorectal cancer using Anti-ELOVL3 [V61 P2B3*D10]. IHC was performed on formalin-fixed, paraffin-embedded tissue sections. Antigen retrieval step is required (microwave 10 min @ 950W in 0.01M sodium citrate buffer, pH 6.0).](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,q_auto/3b8289a0-f3b6-4dd8-9d88-13cb373f3c08.jpg)
![Survival curve comparing patients outcome categorised by expression of ELOVL3 using Anti-ELOVL3 [V61 P2B3*D10]. Strong expression of ELOVL3 was associated with improved patients’ outcome (p=0.022).](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,q_auto/103adb65-30a7-437e-a0b8-c43342ea03fa.png)
![Immunohistochemistry of formalin-fixed, paraffin-embedded human colorectal cancer tissue using anti-ELOVL3 [V61 P2B3*D10] showing strong cytoplasmic staining.](https://res.cloudinary.com/ximbio/image/upload/c_limit,fl_lossy,h_282,q_auto,w_368/a6066eb0-1cf2-4663-81d2-fd122bb28449.jpg)
![Immunohistochemistry was performed on normal colon (A) and primary colorectal tumour (B) tissue using anti-ELOVL3 [V61 P2B3*D10]. Cytoplasmic localisation of ELOVL3 was observed.](https://res.cloudinary.com/ximbio/image/upload/c_limit,fl_lossy,h_282,q_auto,w_368/7b350a61-0a24-4bd4-b8ea-115e7b61ae27.jpg)
![Immunohistochemistry image showing strong cytoplasmic positivity in primary colorectal cancer using Anti-ELOVL3 [V61 P2B3*D10]. IHC was performed on formalin-fixed, paraffin-embedded tissue sections. Antigen retrieval step is required (microwave 10 min @ 950W in 0.01M sodium citrate buffer, pH 6.0).](https://res.cloudinary.com/ximbio/image/upload/c_limit,fl_lossy,h_282,q_auto,w_368/3b8289a0-f3b6-4dd8-9d88-13cb373f3c08.jpg)
![Survival curve comparing patients outcome categorised by expression of ELOVL3 using Anti-ELOVL3 [V61 P2B3*D10]. Strong expression of ELOVL3 was associated with improved patients’ outcome (p=0.022).](https://res.cloudinary.com/ximbio/image/upload/c_limit,fl_lossy,h_282,q_auto,w_368/103adb65-30a7-437e-a0b8-c43342ea03fa.png)
![Image thumbnail for Anti-ELOVL3 [V61 P2B3*D10]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/66f388ef-458a-4bf7-ae60-c1f20bb813a7.jpg)
![Image thumbnail for Anti-ELOVL3 [V61 P2B3*D10]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/db1bb959-28cb-4ca5-9645-ee5770a96265.jpg)
![Image thumbnail for Anti-ELOVL3 [V61 P2B3*D10]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/a6066eb0-1cf2-4663-81d2-fd122bb28449.jpg)
![Image thumbnail for Anti-ELOVL3 [V61 P2B3*D10]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/7b350a61-0a24-4bd4-b8ea-115e7b61ae27.jpg)
![Image thumbnail for Anti-ELOVL3 [V61 P2B3*D10]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/3b8289a0-f3b6-4dd8-9d88-13cb373f3c08.jpg)
![Image thumbnail for Anti-ELOVL3 [V61 P2B3*D10]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/103adb65-30a7-437e-a0b8-c43342ea03fa.png)
| Catalogue Number | 152685 |
| Applications | ELISA IHC WB |
| Antigen/Gene or Protein Targets | ELOVL Fatty Acid Elongase 3 (ELOVL3) |
| Reactivity | Human |
| Relevance | Condensing enzyme that elongates saturated and monounsaturated very long chain fatty acids (VLCFAs). Highest activity toward C18 acyl-CoAs, especially C18:0 acyl-CoAs. |
| Host | Mouse |
| Immunogen | Ovalbumin-conjugated synthetic peptide - QPYNFELSK |
| Positive Control | WB- Jurkat whole cell lysate or overexpression cell lysate; IHC-formalin-fixed, paraffin-embedded multi tumour tissue microarray |
| Subclass | IgG1 kappa |
| Myeloma Used | P3X63Ag8.653 |
| Research Area | Cancer, Cardiovascular, Cell Signaling & Signal Transduction, Metabolism |
References: 2 entries
The expression of brown fat-associated proteins in colorectal cancer and the relationship of uncoupling protein 1 with prognosis.
Europe PMC ID: 30737786
The expression of brown fat associated proteins in colorectal cancer and the relationship of uncoupling protein 1 with prognosis. Alnabulsi et al. 2019. Int J Cancer. :. PMID: 30737786.
Add a reference
References: 2 entries
The expression of brown fat-associated proteins in colorectal cancer and the relationship of uncoupling protein 1 with prognosis.
The expression of brown fat associated proteins in colorectal cancer and the relationship of uncoupling protein 1 with prognosis. Alnabulsi et al. 2019. Int J Cancer. :. PMID: 30737786.
Add a reference
